"HIF-1a: Ready for Prime Time?" symposium to be held on October 22
CAMBRIDGE, Mass., Sept. 23, 2013 /PRNewswire/ -- The role of hypoxia-inducible
factor-1a, or HIF-1a, in solid tumor growth has been well characterized. HIF-1a
is often present in solid tumors where hypoxic conditions are common, and its
presence may be increased by anti-angiogenic medicines and radiation. Because
HIF-1a promotes drug resistance, leaders in government, academia, and industry
have sought an effective HIF-1a inhibitor for more than a decade. Expert
panelists will discuss whether the potential of HIF-1a inhibition is soon to
become a reality.
Cancer specialists are invited to a symposium called HIF-1a: Ready for Prime
Time? on October 22 at Harvard Medical School. Panelists will discuss emerging
evidence that HIF-1a is a master regulator of multiple cancer cell survival
mechanisms, the impact of anti-angiogenic agents and radiotherapy on HIF-1a, and
strategies to effectively inhibit it.
WHO: Open to academics, health care providers, and pharmaceutical industry
professionals interested in the latest research on HIF-1a and the advances that
illustrate its value as a therapeutic target
WHAT: HIF-1a: Ready for Prime Time? includes pre-clinical and clinical panels, a
keynote presentation, a poster exhibition, and a dinner reception
WHEN: Tuesday, October 22, 2013, from 5:30 p.m. to 9:30 p.m.
WHERE: Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue
Louis Pasteur, Boston, MA 02115
REGISTER: Online at www.HIFSymposium.com, via email at email@example.com with
"HIF Symposium" in the subject line, or by phone at 845-265-2155 specifying "HIF
Symposium"; please note institution, degree, and phone number when registering;
there is no fee
The symposium's keynote speaker is Robert A. Weinberg, PhD, Massachusetts
Institute of Technology. Confirmed panel participants include: Sarah Conley,
PhD, of MedImmune and formerly of the Max Wicha Lab at the University of
Michigan; Mark Dewhirst, PhD, of Duke University School of Medicine; Amato
Giaccia, PhD, of Stanford University; William Kaelin, MD, of Harvard Medical
School; Robert Kerbel, PhD, of the University of Toronto; and Giovanni Melillo,
MD, of AstraZeneca and formerly of NCI.
SOURCE Cerulean Pharma Inc.